
| Verifiedfields: | changed |
| Watchedfields: | changed |
| Verifiedrevid: | 414779406 |
| Iupac Name: | 6-allyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[4,5-''d'']azepin-2-amine |
| Image Class: | skin-invert-image |
| Image Class2: | bg-transparent |
| Legal Status: | Rx-only |
| Routes Of Administration: | Oral |
| Tradename: | Domin |
| Synonyms: | Alefexole, B-HT920 |
| Iuphar Ligand: | 5442 |
| Cas Number: | 101626-70-4 |
| Atc Prefix: | none |
| Pubchem: | 5374 |
| Unii: | 7AM2J46Z1Y |
| Chembl: | 1289023 |
| Chemspiderid: | 5181 |
| Index2 Label: | DIHYDROCHLORIDE |
| Cas Number2: | 36085-73-1 |
| Unii2: | 9R6E1D8H1O |
| C: | 10 |
| H: | 15 |
| N: | 3 |
| S: | 1 |
| Smiles: | C=CCN1CCC2=C(SC(N)=N2)CC1 |
| Stdinchi: | 1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12) |
| Stdinchikey: | DHSSDEDRBUKTQY-UHFFFAOYSA-N |
Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's disease in Japan by Boehringer Ingelheim; it was introduced in 1996.[1] As of December 2014 it was not approved for marketing in the US nor in Europe.[2]
Talipexole is a dopamine D2 receptor agonist and interacts with both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.[3]
The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.[3] In Japan, the Ministry of Health, Labour and Welfare mandated in 2008 that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.[4]
The N-alkylation of azepan-4-one [105416-56-6] (1) with allyl bromide in the presence of potassium carbonate gives 1-allyl-azepan-4-one (2). This is halogenated with molecular bromine in acetic acid to give 1-allyl-5-bromohexahydro-4-azepinone (3). The last step involves cyclization with thiourea (4) in refluxing ethanol, completing the synthesis of talipexole (5).